EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response

Ethan Trim iD, Anita Giobbie-Hurder, Tamara A Sussman, David Liu, Megan Insco, Rizwan Haq, F Stephen Hodi, Patrick A Ott, Elizabeth I Buchbinder

Pigment Cell & Melanoma Research · 2025

DOI: 10.1111/pcmr.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, 2025. Verfasst von Ethan Trim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Ipilimumab, Nivolumab, Immunotherapy, Melanoma. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical benefit achieved with ipilimumab + nivolumab combination therapy is typically long lasting. However, late progression, after therapy completion, does occur in a subset of patients. At the time of late progression, immunotherapy options include anti‐PD‐1 monotherapy, anti‐PD‐1/LAG‐3, repeat anti‐PD‐1/CTLA‐4 therapy, or TIL therapy, but the efficacy of these approaches is unknown. To investigate, we evaluated 230 patients with advanced melanoma who received treatment with ipilimumab + nivolumab at Dana‐Farber Cancer Institute between 2015 and 2022 as first‐line treatment. Of these, 111 had an initial response of stable disease (SD) or better for 6 months or longer. Of the 111 deriving clinical benefit, 19 had late progression, 14 while off therapy. Ten of the 14 patients who had late progression off therapy were rechallenged with immune checkpoint inhibition (ICB), either as monotherapy or in combination. Eight out of those 10 patients had clinical benefit of SD or better upon ICB rechallenge. The two who did not benefit from rechallenge had mucosal melanoma (3 patients had mucosal, 7 had cutaneous). The data indicate that clinical benefit upon rechallenge with ICB can be achieved in the majority of patients, specifically those with the cutaneous subtype, although responses are mostly SD and are relatively short lived.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabNivolumabImmunotherapyMelanomaAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedDisease ProgressionAgedAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

immune checkpoint inhibitorsipilimumabmelanomanivolumabrecurrenceretrospective studiessalvage therapy

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Ethan Trim

Zitieren

APA

Trim, E., Giobbie-Hurder, A., Sussman, T. A., Liu, D., Insco, M., Haq, R., Hodi, F. S., Ott, P. A., & Buchbinder, E. I. (2025). Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.70023

Vancouver

Trim E, Giobbie-Hurder A, Sussman TA, Liu D, Insco M, Haq R, et al. Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response. Pigment Cell & Melanoma Research. 2025. doi:10.1111/pcmr.70023

BibTeX
@article{Trim2025,
  author = {Trim, Ethan and Giobbie-Hurder, Anita and Sussman, Tamara A and Liu, David and Insco, Megan and Haq, Rizwan and Hodi, F Stephen and Ott, Patrick A and Buchbinder, Elizabeth I},
  title = {Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response},
  journal = {Pigment Cell & Melanoma Research},
  year = {2025},
  doi = {10.1111/pcmr.70023}
}
Kostenlos starten →